66 reports

  • IV. KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND
  • IV. KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND DEMAND

The total sales volume of monoclonal antibody reached ## million Yuan in 2018.

  • Renal Cancer
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • IV. KIDNEY CANCER TREATMENT DRUGS PRODUCTION AND
  • Kidney Cancer Treatment Drugs Sales Volume and Market Share by Drugs Classification in 2018 (Million Yuan/percent)

Monoclonal antibodies are genetically engineered antibodies that are identical copies of one another.

  • Renal Cancer
  • China
  • Demand
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd

EXECUTIVE SUMMARY ##.

  • Renal Cancer
  • Market Shares
  • Kidney Cancer Treatment Drugs Sales Volume and Market Share by Drugs Classification in 2018 (Million Yuan/percent)
  • Kidney Cancer Treatment Drugs Sales Volume (million

Monoclonal antibodies are genetically engineered antibodies that are identical copies of one another.

  • Renal Cancer
  • China
  • AstraZeneca China Inc.
  • Bayer Schering Pharmaceutical Co., Ltd
  • Roche Group
  • Advanced/Stage IV/Metastatic RCC Pipeline Drug Molecules by Molecule Type
  • d. Tivozanib

Twelve are monoclonal antibody including two antibody-drug conjugates.

  • Renal Cancer
  • Argos Therapeutics, Inc.
  • AstraZeneca PLC
  • AVEO Oncology
  • Bristol-Myers Squibb Company

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • Trade

Monoclonal antibodies such as mepolizumab and omalizumab are sometimes effective.

  • Cough And Cold
  • China
  • Demand
  • Market Size
  • GlaxoSmithKline plc
  • D) PIPELINE BY PROGRAM TYPE
  • UROLOGIC ONCOLOGY, GLOBAL, USAGE OF GENERICS ACROSS KEY INDICATIONS, 2016

Antibody blockade of PD-## has showed promise in the treatment of several malignancies.

  • Renal Cancer
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Johnson & Johnson
  • Pfizer Inc.
  • 8.2 MERCK & CO., INC.
  • 9.4 NOVEL TREATMENT OPTION FOR RENAL CELL CARCINOMA

Nivolumab is a full human monoclonal antibody that binds to a molecule called PD-## on immune cells and promotes anti-tumor effects.

  • Renal Cancer
  • World
  • Exelixis, Inc.
  • Merck & Co., Inc.
  • Rexahn Pharmaceuticals, Inc.
  • MOST PRESCRIBED DRUGS FOR RCC BY CLASS IN THE 8MM

ANTIBODIES TARGETING PD-##, AN IMMUNE CHECKPOINT RECEPTOR, AND PD-L##, THE LIGAND OF PD-##, HAVE FOUND THEMSELVES IN PROMINENT POSITIONS IN THE PORTFOLIOS OF MAJOR COMPANIES IN THE RCC SPACE.

  • Renal Cancer
  • Eisai Co., Ltd.
  • Exelixis, Inc.
  • Pfizer Inc.
  • Roche Group

See what is possible for these therapeutic classes: - Angiogenesis inhibitors - mTOR inhibitors - Monoclonal antibodies (mAbs) - Immunotherapies - Generics and other products.

  • Cancer
  • Renal Cancer
  • Therapy
  • World
  • Market Size

Renal cell cancer

4385 5000 3900
  • Summary of therapeutic classes in renal cell cancer by ATC code
  • PD-L1 INHIBITOR ATEZOLIZUMAB IS BEING INVESTIGATED IN A PHASE III CLINICAL TRIAL IN COMBINATION WITH AVASTIN

Atezolizumab (MPDL##A) is a fully humanized monoclonal antibody that targets programmed death-ligand ## (PD-L##).

  • Renal Cancer
  • European Union
  • Japan
  • North America
  • United States
  • LIST OF KEY APPROVED AND PIPELINE COMPETITIVE DRUGS (RCC)
  • Some of the pipeline drugs in renal cell carcinoma market

Most of these are small molecules except Avastin and the newly-approved Opdivo, which are monoclonal antibodies.

  • Cough And Cold
  • Renal Cancer
  • United States
  • Novartis AG
  • Pfizer Inc.
  • DORMANT PRODUCTS, H2 2019 (CONTD..2), H2 2019

IT IS A MONOCLONAL ANTIBODY.

  • Oncology
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • BioLineRx Ltd.

Pasteur Institute NA NA MONOCLONAL ANTIBODY TO ANTAGONIZE FCGRIIA FOR AUTOIMMUNE ARTHRITIS, PULMONARY INFLAMMATION, SYSTEMIC ANAPHYLAXIS AND THROMBOCYTOPENIA - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description

  • Cough And Cold
  • Therapy
  • United States
  • World
  • Product Initiative
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2018 (CONTD..12), H2 2018

THE DRUG CANDIDATE IS AN IMMUNOGLOBULIN G (IGG) ## CLASS, FULLY HUMAN MONOCLONAL ANTIBODY (MAB).

  • Cancer Immunotherapy
  • Immunotherapy
  • Oncology
  • Renal Cancer
  • Bristol-Myers Squibb Company
  • PIPELINE BY PHARMABCINE INC, H2 2019

MONOCLONAL ANTIBODIES.

  • Hospital
  • Renal Cancer
  • Targeted Therapy
  • Therapy
  • Exelixis, Inc.

The drug contains nivolumab, a human antibody directed against PD-##, as the active ingredient.

  • Renal Cancer
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Novartis AG
  • Pfizer Inc.

IT ACTS BY TARGETING ANGIOPOIETIN ## RECEPTOR (ANG-##) AND PROTEIN KINASE B (AKT).

  • Hospital
  • Renal Cancer
  • Targeted Therapy
  • Therapy
  • Exelixis, Inc.

NGM Bio developed a biologics platform that incorporates multiple technologies to generate and screen monoclonal antibodies.

  • Renal Cancer
  • United States
  • World
  • Product Initiative
  • Eisai Co., Ltd.

It also develops a product CORVUS PHARMACEUTICALS INC ARRIEN PHARMACEUTICALS LLC Pipeline by Corvus Pharmaceuticals Inc, H## 2018 candidate, an anti-CD## monoclonal antibody that inhibits the production of adenosine produced by the tumor cells.

  • Cancer
  • Immunotherapy
  • Renal Cancer
  • Therapy
  • Novartis AG
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H1 2018

The company also develops SNDX-##, a monoclonal antibody that targets the CSF-## receptor.

  • Renal Cancer
  • United States
  • World
  • Company Sales
  • Product Initiative

Most recently she served as the Worldwide Brand Director at Novartis Pharmaceuticals Corporation, where she was the global launch lead for Aimovig®, the first monoclonal antibody approved by the U. S.

  • Clinical Trial
  • Cough And Cold
  • HIV AIDS
  • United States
  • AcelRx Pharmaceuticals, Inc.

THE DRUG CANDIDATE IS A SELECTIVE MONOCLONAL ANTIBODY WHICH TARGETS CXCR## CHEMOKINE RECEPTOR.

  • Cell Therapy
  • Pharmaceutical
  • Renal Cancer
  • Therapy
  • BioLineRx Ltd.

It is a monoclonal antibody.

  • Cancer
  • Cough And Cold
  • Renal Cancer
  • Therapy
  • Merck & Co., Inc.

The drug candidate is a combination of multi-kinase angiogenesis inhibitor and PD-## monoclonal antibody.

  • Cancer
  • Immunotherapy
  • Renal Cancer
  • Therapy
  • Novartis AG
  • TX-250 - DRUG PROFILE
  • AUG 23, 2018: HEIDELBERG PHARMA: PARTNER TELIX PHARMACEUTICALS FILES PHASE III TRIAL FOR KIDNEY CANCER IMAGING IN EUROPE

In July 2013, Radboud University completed a Phase I/ II trial of Increasing doses of Lutetium-## labeled chimeric monoclonal antibody cg## in patients with advanced renal cancer.

  • Brain Cancer
  • Renal Cancer
  • United States
  • World
  • Product Initiative

The drug candidate is a monoclonal antibody that inhibits binding of IL-## to the ST## receptor.

  • Cough And Cold
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

The company develops humanized or fully human monoclonal antibodies.

  • Hepatitis
  • Renal Cancer
  • Japan
  • United States
  • Eisai Co., Ltd.
  • PAZOPANIB HYDROCHLORIDE + PEMBROLIZUMAB - DRUG PROFILE

The company also develops SNDX-##, a monoclonal antibody that targets the CSF-## receptor.

  • Oncology
  • Renal Cancer
  • United States
  • World
  • Product Initiative